Bergen, Norway, 15 March 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, provides an update on BGBC004, an ongoing, company sponsored USA only phase Ib/II clinical trial evaluating bemcentinib in combination with TARCEVA® (erlotinib) in first and second line patients with non-small cell … Read more
Bergen, Norge 19. februar 2018: BerGenBio ASA (OSE: BGBIO) opplyser at selskapet har, tidligere enn planlagt, fullført rekrutteringen av 28 pasienter som var målet i den første av de to delene av det Fase II kliniske forsøket som skal evaluere AXL-hemmeren bemcentinib (BGB324) i kombinasjon med anti-PD-1 terapien KEYTRUDA® (pembrolizumab) som et potensielt nytt behandlingsregime … Read more
Bergen, Norway, 19 February 2018 – BerGenBio ASA (http://www.bergenbio.com) (OSE: BGBIO) announces that it has completed enrolment, ahead of schedule, of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib (BGB324) in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known … Read more
Bergen, Norway, 16 February 2018 – On 9 March 2018 at 11:00 hours (CET) an extraordinary general meeting of BerGenBio ASA will be held in the Company’s offices in Jonas Lies vei 91, 5009 Bergen. The notice, registration form and power of attorney are attached to this release. The notice will be sent to all … Read more
Bergen, Norway, 13 February 2018 – The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) has, to fulfil the Company’s obligations under the option agreements, resolved to increase the Company’s share capital by NOK 1,000 by issuance of 10,000 new shares. The new shares shall be subscribed for by an employee that wishes … Read more
Bergen, Norway, 13 February 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2017. A presentation of the results by the Company’s senior management team will take place today at 10.00 am CET in … Read more
Bergen, 13. februar 2018 – BerGenBio ASA (OSE: BGBIO), et onkologisk bioteknologiselskap i klinisk fase som utvikler ‘first-in-class’ hemmere av Axl kinase mot flere krefttyper, offentliggjør resultatet for fjerde kvartal 2017 og for året som helhet.Selskapets ledelse vil avholde en presentasjon i Oslo i dag klokken 10. Detaljer følger nedenfor.Kommentar fra administrerende direktør Richard Godfrey:«BerGenBio … Read more
Bergen, Norway, 06 February 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib (BGB324), a first-in-class selective small molecule AXL inhibitor, as a potential cornerstone therapy for multiple cancer indications, will announce its results for the fourth quarter and full year 2017 on Tuesday, 13 February 2018. A presentation by … Read more
Favourable interim safety data reported across three phase II clinical trials with bemcentinib in combination with KEYTRUDA® (pembrolizumab) Immune response demonstrated in AML patients treated with bemcentinib monotherapy in phase II clinical trial Two posters featuring four of BerGenBio’s six phase II clinical trials with selective AXL inhibitor bemcentinib presented at the ASCO-SITC Clinical Immuno-Oncology … Read more
Trial aims to evaluate the effectiveness of BGB324 (bemcentinib) in preventing and reversing resistance to targeted therapy Bergen, Norway, January 9, 2018 – BerGenBio ASA (OSE:BGBIO) (http://www.bergenbio.com), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors as a potential cornerstone of combination cancer therapy, announces that the first efficacy endpoint has been met in its … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.